Senior Associate at Asabys, where he joined in 2022. He is responsible for evaluating novel opportunities across multiple therapeutic areas in Biotech and HealthTech. Antonio currently serves as a board observer at Inbrain Neuroelectronics, SafeHeal and ALLOX.
Antonio joined Asabys after working as Investment Analyst at Inkef Capital where he supported the Healthcare team with deal sourcing and the analysis of investment opportunities. Prior to Inkef, Antonio was an Innovation fellow at the Novo Nordisk Foundation Biomedical Design Programme in Copenhagen, where he co-founded a digital health start-up.
Antonio has 9 years of scientific research experience, working at the interface of drug discovery, biology and biophysics. He earned a Ph.D. in Drug Discovery from the University of Naples Federico II, and was a postdoc at FMP-Berlin and at Stanford University.
